DOCSLIB.ORG

Stakeholder Vaccine FAQ, from the Department of Health and Social Care

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Stakeholder Vaccine FAQ, from the Department of Health and Social Care Stakeholder Vaccine FAQ, from the Department of Health and Social Care Please note that text that is highlighted blue has been updated on 6 August by the Department of Health and Social Care. Contents Top lines ........................................................................................................................................................................................ 2 Vaccine deployment statistics ........................................................................................................................................ 2 Top announcements and lines in the last seven days: .................................................................................... 3 Q&A ................................................................................................................................................................................................. 13 Boosters ........................................................................................................................................................................................ 13 Blood clots and the Oxford/AstraZeneca vaccine ................................................................................................ 14 Which vaccines have been authorised in the UK? ................................................................................................ 16 Research, Development and Manufacturing ........................................................................................................... 16 Details on specific vaccines/manufacturers ............................................................................................................ 17 ‘Mix and Match’, Heterologous Prime Boost ........................................................................................................... 22 Vaccine quantities in the UK, availability of supply ............................................................................................ 23 Vaccine Roll Out ...................................................................................................................................................................... 24 Disabilities and vaccine ....................................................................................................................................................... 25 Immunocompromised people ........................................................................................................................................ 26 People who are homeless or rough sleepers ......................................................................................................... 28 Children ....................................................................................................................................................................................... 29 Time between first dose and second dose, changes to dosage interval ................................................. 31 New variants and vaccine effectiveness ................................................................................................................... 32 Vaccine efficacy, length of protection, impact on transmissibility, deaths prevented ................... 36 Vigilance, side effects and adverse incidents ......................................................................................................... 38 Vaccines as a condition of deployment .................................................................................................................... 40 BAME uptake ............................................................................................................................................................................. 41 Working with businesses and the private sector ................................................................................................. 43 COVID-Status certification review (so-called ‘vaccine passports’) ............................................................. 43 Vaccine Passports, International Travel .................................................................................................................... 45 Clinical trials .............................................................................................................................................................................. 47 Ingredients, Controversial Substances, Moral and Ethical Advisory Group (MEAG) ........................ 48 Pregnancy, childbirth, fertility ......................................................................................................................................... 49 Vaccine hesitancy, misinformation, disinformation ........................................................................................... 52 Community Champions scheme (updated 25/01/2021) ................................................................................... 53 Top lines Vaccines are the way out of this pandemic. Vaccines are the best way to protect people from coronavirus and have saved thousands of lives. Vaccinated people are far less likely to get COVID with symptoms. Vaccinated people are even more unlikely to get serious COVID-19, to be admitted to hospital, or to die from it and vaccinated people are less likely to pass the virus to others. The first dose of the vaccine offers good levels of protection, but to get maximum protection everyone must get a second dose, so we are urging all people to come back when they are contacted or if they have an appointment booked. 46.9 million people have now received their first COVID-19 vaccine dose. 39 million have had their second dose. All those aged 18 and over can book their vaccination through the NHS booking service. You can also call 119 free of charge, anytime between 7am and 11pm seven days a week. All adults should have a chance to have a second dose by mid September All 16-and-17-year olds will be offered the vaccine. Initially they should wait to be contacted by their GP to arrange an appointment although walk-in services will soon be available. Children aged 12 to 15 who are clinically vulnerable to COVID or live with adults who are at increased risk of serious illness from the virus will be contacted by the NHS and invited for their vaccine shortly. From 19 July, arrivals who have received two doses of an NHS administered COVID-19 vaccine in the UK (plus 14 days), or are on a formally approved UK vaccine clinical trial, returning to England from amber list counties will no longer need to quarantine From 16 August, people who have received two doses of COVID-19 vaccine will no longer need to self-isolate if they are identified as a close contact of someone with COVID-19. You can book via the NHS website here: https://www.nhs.uk/conditions/coronavirus- covid-19/coronavirus-vaccination/book-coronavirus-vaccination/ The Covid-19 vaccination programme is the biggest vaccination programme in NHS history. Vaccine deployment statistics Latest number on vaccines can be found on the gov.uk coronavirus dashboard here. NHS.uk statistics, updated weekly, can be found here. Total vaccination statistics - up to and including 5 August 2021: UK total first dose: 46,961,830 UK total second dose: 39,047,529 1st dose 2nd dose Total England 39,416,306 32,588,410 72,004,716 1st dose 2nd dose Total Scotland 4,020,712 3,286,153 7,306,865 Wales 2,300,137 2,099,624 4,399,761 Northern Ireland 1,224,675 1,073,342 2,298,017 Top announcements and lines in the last seven days: NHS release - One million children and young people can get NHS COVID jab (06.08.21) More than a million children and young people can get the COVID jab in the latest stage of the NHS vaccination programme, the biggest and most successful in health service history. The NHS has worked to rapidly extend the programme to 16 and 17 year olds, the country’s most vulnerable children and those who live with vulnerable adults following changes in guidance from the Joint Committee on Vaccination and Immunisation (JCVI). All 16-and-17-year olds will be offered one jab dose of the vaccine, under the new guidance issued by the JCVI earlier this week. Initially, they should wait to be contacted by their GP to arrange an appointment although walk-in services will soon be available to everyone aged 16 and over. While children and young people can get coronavirus, there are fewer cases compared to adults and symptoms are usually mild. Dr Nikki Kanani, NHS medical director for primary care and deputy SRO for the vaccine programme said : “NHS staff have delivered 70 million COVID-19 vaccines across England in just over seven months, giving protection against coronavirus to more than 39 million people and saving thousands of lives. “The NHS has also worked hard to put the JCVI guidance into action as swiftly as possible and I am pleased to say that one million children and young people will now be able to get the vaccine, protecting themselves, their family and their friends. “The COVID-19 vaccine is safe and effective and I urge anyone eligible of any age to come forward and take up the offer.” Health and Social Care Secretary, Sajid Javid said : “COVID-19 vaccines have saved more than 60,000 lives and prevented 22 million infections in England alone. They are building a wall of defence against the virus and are the best way to protect people from serious illness. “The NHS have worked hard to put the JCVI’s independent and expert advice into action to roll out this new stage of our ground breaking vaccination
Load more

Recommended publications
  • (Public Pack)Minutes Document for London Assembly (Plenary), 04/02
    MINUTES Meeting: London Assembly (Plenary) Date: Thursday 4 February 2021 Time: 10.00 am Place: Virtual Meeting Copies of the minutes may be found at: http://www.london.gov.uk/mayor-assembly/london- assembly/whole-assembly Present: Navin Shah AM (Chair) Susan Hall AM Tony Arbour AM (Deputy Chairman) David Kurten AM Jennette Arnold OBE AM Joanne McCartney AM Shaun Bailey AM Dr Alison Moore AM Siân Berry AM Steve O'Connell AM Andrew Boff AM Caroline Pidgeon MBE AM Léonie Cooper AM Keith Prince AM Unmesh Desai AM Murad Qureshi AM Tony Devenish AM Caroline Russell AM Len Duvall AM Dr Onkar Sahota AM Florence Eshalomi AM MP Peter Whittle AM Nicky Gavron AM City Hall, The Queen’s Walk, London SE1 2AA Enquiries: 020 7983 4100 minicom: 020 7983 4458 www.london.gov.uk v1 2015 Greater London Authority London Assembly (Plenary) Thursday 4 February 2021 1 Apologies for Absence and Chair's Announcements (Item 1) 1.1 The Chair explained that in accordance with Government regulations, the meeting was being held on a virtual basis, with Assembly Members participating remotely. 1.2 The Clerk read the roll-call of Assembly Members who were participating in the meeting. Apologies for absence were received on behalf of Gareth Bacon AM MP and Andrew Dismore AM. 1.3 On behalf the London Assembly the Chair expressed condolences to Captain Sir Tom Moore’s family following his death, noting the hope and happiness he had brought to many during the COVID-19 pandemic. 1.4 The Chair provided an update on recent Assembly activity, including: the London Assembly’s Plenary meeting questioning the Mayor on his draft 2021/22 budget; the COVID-19 and homeworking event held to explore the impact of working from home mental and physical wellbeing; and the Fire, Resilience and Emergency Planning Committee’s meeting with the London Fire Commissioner, on the impacts of COVID-19 on the London Fire Brigade.
    [Show full text]
  • To Approve Pfizer-Biontech Vaccine: UK Regulator 2 December 2020
    No 'corners cut' to approve Pfizer-BioNTech vaccine: UK regulator 2 December 2020 the jab began in June after interim results from early trials by US giant Pfizer and German newcomer BioNTech became available. "If you climb a mountain, you prepare and prepare," she added. "On 10th November we were at base camp. When we got the final analysis we were ready for that last sprint that takes us to today." British Health Secretary Matt Hancock said earlier the country's state-run National Health Service will start inoculations with 800,000 doses "early next week". Credit: Pixabay/CC0 Public Domain That will be ramped up to "millions" of jabs by the end of the year. Britain's independent medicines regulator said on The mass vaccination programme will begin with Wednesday no "corners have been cut" in its elderly care home residents and frontline health recommendation to approve Pfizer-BioNTech's and social care staff. COVID-19 vaccine for general use. © 2020 AFP The Medicines and Healthcare products Regulatory Agency (MHRA) said it had used overlapping trials and "rolling reviews" since June to reach the determination in record time. "That doesn't mean any corners have been cut—none at all," June Raine, its chief executive, said at a press conference. "The safety of the public will always come first." Wednesday's announcement saw Britain become the first Western country to approve a COVID-19 vaccine for general use, with jabs set to begin for the most vulnerable from next week. The Pfizer-BioNTech vaccine is one of several expected to gain regulatory approval in the coming weeks as similar reviews are completed.
    [Show full text]
  • Anna Frances Request-746058-E0cf701a
    Anna Frances MHRA [email protected] 10 South Colonnade Canary Wharf London E14 4PU United Kingdom www.gov.uk/mhra 7th May 2021 Dear Ms Frances, FOI 21/409 Thank you for your emails to MHRA customer services on 12th April 2021, where you asked questions relating to the COVID-19 vaccines, particularly inquiring on data on thromboembolic events and low platelets. In addition, you requested evidence of informed consent before people receive COVID-19 vaccines. Information on thromboembolic events and low platelets following a COVID-19 vaccine The MHRA has been proactively monitoring the safety of all approved COVID-19 vaccines for near real-time safety monitoring at the population level. A summary of Yellow Card reporting concerning the COVID-19 vaccines is published each week and can be found here. In this publication, you will find the specific information you have requested surrounding these case reports, including a breakdown of the age and sex of these patients and how many reports were fatal. The estimated number of first doses of COVID-19 Vaccine AstraZeneca administered in the UK by 28th April was 22.6 million and 5.9 million estimated second doses, giving an overall case incidence of 10.5 per million doses. Taking into account the different numbers of patients vaccinated with COVID-19 Vaccine AstraZeneca in different age groups, there is a higher reported incidence rate in the younger adult age groups compared to the older groups. MHRA advises that this evolving evidence should be taken into account when considering the use of the vaccine.
    [Show full text]
  • UK Warns People with Serious Allergies to Avoid Pfizer Vaccine After Two Adverse Reactions
    UK warns people with serious allergies to avoid Pfizer vaccine after two adverse reactions DECEMBER 9, 2020 By Alistair Smout LONDON (Reuters) -Britain’s medicine regulator has advised that people with a history of significant allergies do not get Pfizer-BioNTech’s COVID-19 vaccine after two people reported adverse reactions on the first day of rollout. George Dyer, 90, receives the first Pfizer/BioNTech COVID-19 vaccine, administered by General manager of Covid Recovery Becky Board, at Croydon's University Hospital, on the first day of the largest immunisation programme in the British history, in London, Britain December 8, 2020. Dan Charity/Pool via REUTERS Starting with the elderly and frontline workers, Britain began mass vaccinating its population on Tuesday, part of a global drive that poses one of the biggest logistical challenges in peacetime history. National Health Service medical director Stephen Powis said the advice had been changed after two NHS workers reported anaphylactoid reactions associated with receiving the vaccine. They were among the thousands who received the shot on Tuesday. “As is common with new vaccines the MHRA (regulator) have advised on a precautionary basis that people with a significant history of allergic reactions do not receive this vaccination, after two people with a history of significant allergic reactions responded adversely yesterday,” Powis said. “Both are recovering well.” The MHRA said it would seek further information and was investigating as a matter of priority, and Pfizer and BioNTech said they were supporting the MHRA’s investigation. Last week Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) became the first in the world to approve the vaccine, developed by Germany’s BioNTech and Pfizer, while the U.S.
    [Show full text]
  • Legal-Graphics' 6-18-21 COVID Timeline
    Number of days since first sign of virus Overview: Year 2 of COVID Year 2 Nov. 23, 2020 Dec. 3, 2020 Dec. 11, 2020 Dec. 21, 2020 Dec. 30, 2020 Jan. 7, 2021 Jan.Jan. 14,7, 2021 2021 of COVID-19 Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths over 1,400,000 over 1,500,000 over 1,600,000 over 1,700,000 over 1,800,000 over 1,900,000 over 1,900,0002,000,000 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 Link to Nov. 16, 2020 Nov. 18, 2020 Nov. 21, 2020 Nov. 25, 2020 Nov. 27, 2020 Nov. 30, 2020 Dec. 3, 2020 Dec. 6, 2020 Dec. 8, 2020 Dec. 11, 2020 Dec. 14, 2020 Dec. 17, 2020 Dec. 21, 2020 Dec. 22, 2020 Dec. 26, 2020 Dec. 29, 2020 Dec. 31, 2020 Jan. 3, 2021 Jan. 5, 2021 Jan. 8, 2021 Jan. 11, 2021 Jan. 13, 2021 Jan. 17, 2021 Source Moderna says data FDA allows US cases top Picture of US Demand for live Moderna to request Map showing US UK gears up for Chart of cumulative Pfizer vaccine to be How do the Pfizer Vaccinations reach How the Pfizer Vaccines across Could AZD7442 Map showing How vaccinations Interactive US Map It’s lockdown No.
    [Show full text]
  • Coronavirus Vaccination in Devon Briefing #22 – 4 June 2021
    Coronavirus Vaccination in Devon Briefing #22 – 4 June 2021 Key messages • 769,059 people in Devon received a first vaccine dose between 8 December and 30 May, while 553,204 second doses have been given. This means 1,322,263 doses have been given in Devon. More than three quarters of adults (aged 16+) in Devon have had at least one dose and over half have had both doses. • Pfizer/Biontech has been approved for use in 12-15 year olds by MHRA • The Janssen vaccine has been approved by the MHRA • People who will be aged 30 and over on 1 July 2021 are currently eligible to book their vaccination. • People are being urged to book and turn up to their second dose appointment. • Two new pharmacy sites are now available through the National Booking Service in Kingsbridge and Plympton. Pfizer/Biontech vaccine approved for use in 12-15 year olds • An extension to the current UK approval of the Pfizer/BioNTech COVID-19 vaccine that allows its use in 12- to 15-year-olds has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). • This follows a rigorous review of the safety, quality and effectiveness of the vaccine in this age group by the MHRA and the Government’s independent advisory body, the Commission on Human Medicines (CHM). • Dr June Raine, MHRA Chief Executive said: “We have carefully reviewed clinical trial data in children aged 12 to 15 years and have concluded that the Pfizer/BioNTech COVID-19 vaccine is safe and effective in this age group and that the benefits of this vaccine outweigh any risk.
    [Show full text]
  • COVID-19 Vaccines and Allergy Ortega Rodríguez NR
    1 The century of mRNA vaccines: COVID-19 vaccines and allergy Ortega Rodríguez NR1,5, Audícana Berasategui MT2,5, de la Hoz Caballer B3,5, Valero Santiago A4,5 1Allergy and Clinical Immunology Service, H.U. Gran Canaria, Dr. Negrín ULPGC, Las Palmas, Spain 2Allergy and Clinical Immunology Service, H.U. Araba, Vitoria-Gasteiz, Spain 3Allergy Service, H.U. Ramón y Cajal, Madrid, Spain 4Allergy Section, Hospital Clínic, IDIBAPS, Barcelona, Spain 5Spanish Society of Allergology and Clinical Immunology (SEAIC) Group Corresponding author: Dr. Nancy Raquel Ortega Rodríguez Servicio de Alergia H.U. de Gran Canaria Dr. Negrín Bco de la Ballena s/n 35010 Las Palmas de G.C. Islas Canarias. Spain E-mail: [email protected] J Investig Allergol Clin Immunol 2021; Vol. 31(1) © 2021 Esmon Publicidad doi: 10.18176/jiaci.0665 2 Key words: COVID-19 vaccines. Coronavirus. Allergy. PEG. Vaccine excipients. Palabras clave: Vacuna COVID-19. Coronavirus. Alergia. PEG. Excipentes de vacuna. On 2 December 2020, the COVID-19, mRNA BNT162b2 vaccine was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and six days later, UK began mass vaccina- tion. Only 24 hours after, Dr June Raine, Chief Executive of MHRA, issued updated guidance to COVID-19 vaccination centers about the management of anaphylaxis, following two reports of anaphylaxis and one report of a possible allergic reaction following immunization. The guidelines say verbatim “Any person with a history of anaphylaxis to a vaccine, medicine or food should not receive the Pfizer/BioNTech vaccine. A second dose should not be given to anyone who has experi- enced anaphylaxis following administration of the first dose of this vaccine.” [1].
    [Show full text]
  • Covid-19: First UK Vaccine Safety Data Are “Reassuring,” Says Regulator
    NEWS BMJ: first published as 10.1136/bmj.n363 on 8 February 2021. Downloaded from London Cite this as: BMJ 2021;372:n363 Covid-19: First UK vaccine safety data are “reassuring,” says regulator http://dx.doi.org/10.1136/bmj.n363 Ingrid Torjesen Published: 08 February 2021 The UK’s medicines regulator has described the first reports after the AstraZeneca-Oxford vaccine. Philip safety data related to covid-19 vaccines as Bryan, vaccine safety lead at the MHRA, said, “Bell’s “reassuring,” with most side effects reported being palsy is something that can also happen naturally, mild and in line with those seen with other types of so its association with the vaccine hasn’t been vaccine. “The benefits continue to far outweigh the established.” The MHRA is investigating the risks,” said June Raine, chief executive of the association more thoroughly using the Clinical Medicines and Healthcare Products Regulatory Practice Research Datalink—a database of Agency (MHRA). anonymised GP records covering about 20% of the population. The agency published yellow card data for covid-19 vaccines given between 9 December 2020 and 24 The MHRA received 107 reports of death after the January 2021, which comprise 22 820 reports from 7 Pfizer-BioNTech vaccine, 34 after the 164 387 first doses and 474 156 second doses.1 Most AstraZeneca-Oxford vaccine, and 2 in which the brand of the reports (16 756) are from people who received of vaccine was unspecified. Most reports were for the Pfizer-BioNTech vaccine, and these list 49 472 older people or people with underlying illness, the suspected reactions.
    [Show full text]
  • Coronavirus: Covid-19 Vaccine Roll-Out Frequently Asked Questions
    By Elizabeth Rough, Tom Powell Coronavirus: Covid-19 vaccine 15 September 2021 roll-out frequently asked questions Summary 1 Key resources 2 FAQs: vaccine costs and quantities 3 FAQs: immunity and transmission 4 FAQs: vaccine safety 5 FAQs: vaccine roll-out 6 FAQs: priority groups 7 FAQs: Other questions commonslibrary.parliament.uk Number CBP 9081 Coronavirus: Covid-19 vaccine roll-out frequently asked questions Image Credits Clear glass vials – pxfuel.com by Pixfuel – no copyright required / image cropped. Disclaimer The Commons Library does not intend the information in our research publications and briefings to address the specific circumstances of any particular individual. We have published it to support the work of MPs. You should not rely upon it as legal or professional advice, or as a substitute for it. We do not accept any liability whatsoever for any errors, omissions or misstatements contained herein. You should consult a suitably qualified professional if you require specific advice or information. Read our briefing ‘Legal help: where to go and how to pay’ for further information about sources of legal advice and help. This information is provided subject to the conditions of the Open Parliament Licence. Feedback Every effort is made to ensure that the information contained in these publicly available briefings is correct at the time of publication. Readers should be aware however that briefings are not necessarily updated to reflect subsequent changes. If you have any comments on our briefings please email [email protected]. Please note that authors are not always able to engage in discussions with members of the public who express opinions about the content of our research, although we will carefully consider and correct any factual errors.
    [Show full text]
  • 12:30 on Tuesday 15 June 2021 Chair
    AGENDA FOR BOARD MEETING HELD IN PUBLIC 10:00 – 12:30 on Tuesday 15 June 2021 Chair: Stephen Lightfoot AGENDA ITEM PURPOSE PRESENTER 10:00 INTRODUCTION 1. What are the priorities for this meeting and how will Information Chair the meeting run? 2. Are there any Apologies or new Declarations of Information All Interest? 3. What were the minutes and actions from the last Approval Chair meeting? 10:10 FINANCIAL SUSTAINABILITY 4. What were the financial results of the MHRA in Approval Jon Fundrey 2020/21? and Michael Whitehouse 10:30 GOVERNANCE 5. How well does the draft text of the Annual Report Approval Rachel reflect the performance of the MHRA in 2020/21? Bosworth and Michael Whitehouse 10:50 CURRENT CONTEXT 6. What are the current key issues from the CEO’s Discussion June Raine point of view? 11:15 HEALTHCARE ACCESS 7. What are the strategic priorities for the development Discussion Sam of the Innovative Licencing & Access Pathway? Atkinson 11:40 PATIENT SAFETY 8. What assurance can be provided by the Patient Assurance Mercy Safety & Engagement Committee? Jeyasingham 12:00 EXTERNAL PERSPECTIVE 9. What questions do members of the public have for - Chair the MHRA Board? 12:30 CLOSE OF MEETING - Chair Item 03 MHRA 040-2021 Medicines and Healthcare products Regulatory Agency Minutes of the Board Meeting Held in Public of 18th May 2021 (10:00 – 12:30) By Zoom Webinar Present: The Board Stephen Lightfoot Chair Professor David Webb CBE Deputy Chair Dr June Raine CBE Chief Executive Dr Barbara Bannister MBE Non-Executive Director Amanda Calvert
    [Show full text]
  • Science and Technology Committee Health and Social Care Committee Oral Evidence: Coronavirus: Lessons Learnt, HC 877
    Science and Technology Committee Health and Social Care Committee Oral evidence: Coronavirus: lessons learnt, HC 877 Wednesday 9 December 2020 Ordered by the House of Commons to be published on 9 December 2020. Watch the meeting Members present: Science and Technology Committee: Greg Clark (Chair); Aaron Bell; Chris Clarkson; Katherine Fletcher; Carol Monaghan; Graham Stringer; Zarah Sultana. Health and Social Care Committee: Jeremy Hunt; Rosie Cooper; Dr James Davies; Dr Luke Evans; Neale Hanvey; Barbara Keeley; Taiwo Owatemi; Sarah Owen; Dean Russell; Laura Trott. Questions 770 - 865 Witnesses I: Sir Patrick Vallance, Government Chief Scientific Adviser; Professor Chris Whitty, Chief Medical Officer for England; Dr Jenny Harries, Deputy Chief Medical Officer, Department for Health and Social Care; and Dr June Raine, Chief Executive, Medical and Healthcare products Regulatory Agency. Examination of witnesses Witnesses: Sir Patrick Vallance, Professor Whitty, Dr Harries and Dr Raine. Q770 Chair: Welcome to this joint hearing of the Health and Social Care and Science and Technology Select Committees, as part of our joint inquiry into what lessons can be learnt from our response to the Covid pandemic so far. I am delighted to welcome the Government’s chief scientific adviser, Sir Patrick Vallance, the chief medical officer for England, Professor Chris Whitty, and the deputy CMO, Dr Jenny Harries. All have been regular contributors to the hearings of our separate Committees, and we are very grateful for that. We are particularly grateful for their appearance today, given that this session is specifically looking back at the course of the pandemic and learning some early lessons from that.
    [Show full text]
  • The Guardian.2021.06.06 [Sun, 06 Jun 2021] 2021.06.06 - Opinion Just Enjoy Your Success, Kate Winslet
    2021.06.06 - Opinion Headlines friday 4 june 2021 2021.06.04 - Coronavirus 2021.06.04 - Spotlight 2021.06.04 - Opinion 2021.06.04 - Around the world Headlines saturday 5 june 2021 2021.06.05 - Coronavirus 2021.06.05 - Opinion 2021.06.05 - Around the world Headlines thursday 3 june 2021 2021.06.03 - Coronavirus 2021.06.03 - Spotlight 2021.06.03 - Opinion 2021.06.03 - Around the world 2021.06.06 - Opinion Just enjoy your success, Kate Winslet. Your husband can take care of himself Tell me how you’ll use my medical data. Only then might I sign up The Observer view on the cost of scrimping on education spending The Observer view on the G7 summit Going on holiday? Not if the Delta variant has its way – cartoon Despite everything, we’re no unhappier than we were a year ago Memo to the G7 spouses: do say ‘nice doggie’, don’t say ‘Cummings’ Have more than 100% of older people been vaccinated? Letters: the complexity of assisted dying For the record Scroungers, lefty lawyers... the Tories duck scrutiny by inventing enemies | Next | Section menu | Main menu | OpinionKate Winslet Just enjoy your success, Kate Winslet. Your husband can take care of himself Barbara Ellen The actor’s ‘ocean warrior’ spouse does what wives do each day, so why the huge praise? Kate Winslet and husband Edward Abel Smith at a Hollywood Film Awards ceremony in Los Angeles. Photograph: Frazer Harrison/Getty Images Kate Winslet and husband Edward Abel Smith at a Hollywood Film Awards ceremony in Los Angeles.
    [Show full text]